

Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司 *
KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT

**CLINICAL TRIAL OF KX-826 AND MINOXIDIL COMBINATION
THERAPY FOR THE TREATMENT OF MALE AGA RECEIVED
CLEARANCE BY CHINA NMPA**

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to update its shareholders and potential investors on the latest information related to the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the phase Ib/III clinical trial of KX-826, a potential first-in-class drug developed by the Group, in combination with minoxidil for the treatment of androgenetic alopecia (“**AGA**”) of male adults (the “**Phase Ib/III Clinical Trial**”) was cleared by the National Medical Products Administration (the “**NMPA**”). This trial is aimed to evaluate the efficacy and safety of KX-826 in combination with minoxidil for the treatment of male adults with AGA in China.

KX-826 is one of the core drugs of the Group. Since its development, it has completed multiple clinical trials for the treatment of male and female AGA in China and the United States, which has demonstrated excellent safety profile and efficacy trend. Minoxidil, approved by the US Food and Drug Administration (the “**FDA**”) in 1988, is one of the mainstream approved drugs for the treatment of AGA. The Group believes that through the development of combination therapy, the value of KX-826 for AGA will be further discovered. In the meanwhile, the Group is also conducting or planning

multiple clinical trials of KX-826 for the treatment of AGA and acne, continuing to explore the value of KX-826 in the field of dermatology.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that KX-826 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, 1 February 2024

As at the date of this announcement, the executive Directors are Dr. Youzhi Tong, Dr. Qun Lu and Dr. Xiang Ni; the non-executive Directors are Mr. Weipeng Gao, Ms. Geqi Wei and Mr. Chengwei Liu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

** For identification purpose only*